北陆药业(300016) - 2020 Q1 - 季度财报

Financial Performance - Total revenue for Q1 2020 was CNY 125,780,404.40, a decrease of 27.08% compared to CNY 172,496,046.39 in the same period last year[8]. - Net profit attributable to shareholders was CNY 26,784,624.69, down 33.97% from CNY 40,566,026.83 year-on-year[8]. - Basic earnings per share decreased by 34.94% to CNY 0.0540 from CNY 0.0830 in the previous year[8]. - The company achieved operating revenue of 125.78 million yuan, a year-on-year decrease of 27.08%[26]. - The net profit attributable to shareholders was 26.78 million yuan, down 33.97% year-on-year[26]. - The net profit after deducting non-recurring gains and losses was 27.82 million yuan, a decrease of 29.34% year-on-year[26]. - Operating profit for the quarter was CNY 31,103,889.25, a decline of 34.5% from CNY 47,558,690.18 year-over-year[48]. - The company's total revenue for the current period is ¥123,348,686.76, a decrease of 28.5% compared to ¥172,496,046.39 in the previous period[52]. - The net profit for the current period is ¥29,746,143.32, down 26.7% from ¥40,566,026.83 in the previous period[52]. - Basic and diluted earnings per share for the current period are both ¥0.0600, compared to ¥0.0830 in the previous period, reflecting a decrease of 27.7%[54]. - Operating profit for the current period is ¥35,588,018.26, a decline of 25.2% from ¥47,558,690.18 in the previous period[52]. Cash Flow and Assets - Net cash flow from operating activities increased by 13.58% to CNY 54,574,319.53 compared to CNY 48,047,149.38 in the same period last year[8]. - The company reported a cash balance of approximately ¥309.54 million as of March 31, 2020, compared to ¥248.40 million at the end of 2019, reflecting a significant increase of 24.56%[39]. - The total current assets increased to approximately ¥602.54 million from ¥550.89 million, marking a growth of 9.38%[39]. - Cash and cash equivalents stood at CNY 295,536,615.03, an increase from CNY 248,404,445.77[44]. - Cash and cash equivalents at the end of the period amount to ¥299,439,473.63, up from ¥230,455,683.07 at the end of the previous period[58]. - Operating cash flow net amount for the first quarter was CNY 53,512,915.68, an increase of 11.4% compared to CNY 48,047,149.38 in the previous period[61]. - Total cash inflow from operating activities was CNY 185,080,182.51, down 9.7% from CNY 204,935,932.43 in the previous period[61]. - Cash outflow from operating activities totaled CNY 131,567,266.83, a decrease of 16.1% compared to CNY 156,888,783.05 in the previous period[61]. - Cash paid for the purchase of fixed assets was CNY 6,779,948.02, down from CNY 9,050,978.62 in the previous period[61]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,932,110,468.10, an increase of 18.99% from CNY 1,623,818,110.94 at the end of the previous year[8]. - The company’s total assets increased to approximately ¥1.93 billion from ¥1.62 billion, representing a growth of 19.06%[41]. - The company’s total liabilities increased to approximately ¥602.54 million, reflecting a rise in short-term borrowings and accounts payable[41]. - Total liabilities increased to CNY 144,672,590.32, compared to CNY 173,311,009.64 in the previous period[46]. - The company's equity attributable to shareholders rose to CNY 1,483,436,290.76, up from CNY 1,450,507,101.30[46]. Shareholder Information - The total number of shareholders at the end of the reporting period was 35,173[12]. - The largest shareholder, Wang Daixue, holds 22.37% of the shares, totaling 110,683,213 shares[12]. - The company did not engage in any repurchase transactions during the reporting period[13]. Operational Changes and Strategies - The company completed the acquisition of actual control over Haichang Pharmaceutical, becoming its controlling shareholder[20]. - The company plans to conduct targeted market promotion efforts as the domestic pandemic situation improves[26]. - The company is focusing on enhancing its product line through independent research and development, as well as through partnerships and acquisitions[29]. - The company has established a pandemic response team to adapt its operational strategies in light of the COVID-19 pandemic[30]. - The company plans to closely monitor the sales of its product, Glimepiride tablets, which was selected for the second round of national centralized procurement[28]. Expenses and Costs - Total operating costs amounted to CNY 102,031,280.26, down 20.7% from CNY 128,591,522.01 in the prior period[48]. - The company’s management expenses increased by 36.22% year-on-year to 14.78 million yuan, primarily due to stock incentive expenses[23]. - The company incurred research and development expenses of ¥11,026,965.70, an increase from ¥10,212,361.77 in the previous period[52]. - The company reported a decrease in sales expenses to ¥34,606,108.82 from ¥50,293,967.82 in the previous period, reflecting a reduction of 31.1%[52]. Other Financial Metrics - The company reported a significant increase in construction in progress, with a balance of 240.21 million yuan, up 8859.75% from the beginning of the period[21]. - Long-term equity investments at the end of the period were 207.45 million yuan, a decrease of 43.17% due to the consolidation of Haichang Pharmaceutical[21]. - Accounts receivable at the end of the period was 102.77 million yuan, a decrease of 35.49% from the beginning of the period[21]. - The company reported a net credit impairment loss of CNY 2,748,880.47, compared to CNY 179,090.55 in the previous period[48]. - Deferred income tax liabilities were CNY 29,622,644.43, slightly down from CNY 29,820,292.99[46]. - The company did not undergo an audit for the first quarter report[62]. - The company did not report any cash inflow from financing activities during the quarter[61]. - The company did not apply new revenue and leasing standards for the first quarter[62].